Characterization of the dopaminergic regulation of human prolactin-secreting cells cultured on extracellular matrix

Cynthia Bethea, J. S. Ramsdell, R. B. Jaffe, C. B. Wilson, R. I. Weiner

    Research output: Contribution to journalArticle

    34 Citations (Scopus)

    Abstract

    Human PRL-secreting adenoma cells were cultured on an extracellular matrix (ECM) secreted by bovine corneal endothelial cells, and their sensitivity to dopamine and dopaminergic agonists was examined. Cells plated on ECM attach rapidly, adopt a flattened morphology, and maintain stable PRL secretion for several weeks. Dopamine inhibited PRL secretion from tumor and nontumor cells on ECM in a dose-dependent fashion, with IC 50 values of 243 ± 29 and 76 ± 3.3 nM, respectively, and a maximal inhibition of 80% at 10 -5 M. Apomorphine (APO), dihydroergocryptine (DHE), and bromocriptine (CB-154) also inhibited PRL secretion from adenoma cells in a dose-dependent fashion, with IC 50 values of 24 ± 13, 0.35 ± 0.1, and 0.05 ± 0.01 nM, respectively. Thus, the rank order of potency of the dopamine agonists in inhibiting PRL secretion from adenoma cells was consistent with an interaction at a dopamine receptor: CB-154 > DHE > APO > dopamine. The dopamine antagonists, d-butaclamol, spiperone, domperidone, chlorpromazine, and l-butaclamol, reversed the inhibitory effect of DHE on PRL secretion with IC 50 values of 0.8 nM, 0.9 nM, 1.3 nM, 80 nM, and 30 μM, respectively. The inhibition of PRL secretion was stereoselective, since d-butaclamol was approximately 2000 times more potent than the inactive l-isomer in reversing the effect of DHE. Pieces of adenomas incubated with dopamine before dispersion responded similarly to the dispersed cells plated on ECM, indicating that the ECM did not appear to alter the dopamine-mediated inhibition of PRL. In summary, human PRL-secreting adenoma cells cultured on ECM respond to dopamine in a dose-dependent fashion, but with an IC 50 slightly greater than that observed with normal mammotrophs. The rank order of potency of the dopamine agonists to inhibit PRL secretion (CB-154 > DHE > APO > dopamine) and the rank order of potency of the dopamine antagonists to reverse the inhibitory effect of DHE (d-butaclamol ≃ spiperone ≥ domperidone > chlorpromazine > l-butaclamol) are consistent with an interaction at a dopamine receptor and correlate with the ability of these agents to displace [ 3H]DHE in membrane-binding preparations. These data would argue that human PRL-secreting adenoma cells possess a dopamine receptor, both of high affinity and stereoselective, which mediates the inhibition of PRL secretion.

    Original languageEnglish (US)
    Pages (from-to)893-902
    Number of pages10
    JournalJournal of Clinical Endocrinology and Metabolism
    Volume54
    Issue number5
    StatePublished - 1982

    Fingerprint

    Dihydroergocryptine
    Butaclamol
    Prolactin
    Extracellular Matrix
    Cultured Cells
    Adenoma
    Cells
    Dopamine
    Bromocriptine
    Dopamine Agonists
    Apomorphine
    Dopamine Receptors
    Domperidone
    Spiperone
    Dopamine Antagonists
    Chlorpromazine
    Endothelial cells
    Isomers
    Tumors
    Endothelial Cells

    ASJC Scopus subject areas

    • Biochemistry
    • Endocrinology, Diabetes and Metabolism

    Cite this

    Characterization of the dopaminergic regulation of human prolactin-secreting cells cultured on extracellular matrix. / Bethea, Cynthia; Ramsdell, J. S.; Jaffe, R. B.; Wilson, C. B.; Weiner, R. I.

    In: Journal of Clinical Endocrinology and Metabolism, Vol. 54, No. 5, 1982, p. 893-902.

    Research output: Contribution to journalArticle

    @article{5ca933a4b4974c55a72b85056f27aa8a,
    title = "Characterization of the dopaminergic regulation of human prolactin-secreting cells cultured on extracellular matrix",
    abstract = "Human PRL-secreting adenoma cells were cultured on an extracellular matrix (ECM) secreted by bovine corneal endothelial cells, and their sensitivity to dopamine and dopaminergic agonists was examined. Cells plated on ECM attach rapidly, adopt a flattened morphology, and maintain stable PRL secretion for several weeks. Dopamine inhibited PRL secretion from tumor and nontumor cells on ECM in a dose-dependent fashion, with IC 50 values of 243 ± 29 and 76 ± 3.3 nM, respectively, and a maximal inhibition of 80{\%} at 10 -5 M. Apomorphine (APO), dihydroergocryptine (DHE), and bromocriptine (CB-154) also inhibited PRL secretion from adenoma cells in a dose-dependent fashion, with IC 50 values of 24 ± 13, 0.35 ± 0.1, and 0.05 ± 0.01 nM, respectively. Thus, the rank order of potency of the dopamine agonists in inhibiting PRL secretion from adenoma cells was consistent with an interaction at a dopamine receptor: CB-154 > DHE > APO > dopamine. The dopamine antagonists, d-butaclamol, spiperone, domperidone, chlorpromazine, and l-butaclamol, reversed the inhibitory effect of DHE on PRL secretion with IC 50 values of 0.8 nM, 0.9 nM, 1.3 nM, 80 nM, and 30 μM, respectively. The inhibition of PRL secretion was stereoselective, since d-butaclamol was approximately 2000 times more potent than the inactive l-isomer in reversing the effect of DHE. Pieces of adenomas incubated with dopamine before dispersion responded similarly to the dispersed cells plated on ECM, indicating that the ECM did not appear to alter the dopamine-mediated inhibition of PRL. In summary, human PRL-secreting adenoma cells cultured on ECM respond to dopamine in a dose-dependent fashion, but with an IC 50 slightly greater than that observed with normal mammotrophs. The rank order of potency of the dopamine agonists to inhibit PRL secretion (CB-154 > DHE > APO > dopamine) and the rank order of potency of the dopamine antagonists to reverse the inhibitory effect of DHE (d-butaclamol ≃ spiperone ≥ domperidone > chlorpromazine > l-butaclamol) are consistent with an interaction at a dopamine receptor and correlate with the ability of these agents to displace [ 3H]DHE in membrane-binding preparations. These data would argue that human PRL-secreting adenoma cells possess a dopamine receptor, both of high affinity and stereoselective, which mediates the inhibition of PRL secretion.",
    author = "Cynthia Bethea and Ramsdell, {J. S.} and Jaffe, {R. B.} and Wilson, {C. B.} and Weiner, {R. I.}",
    year = "1982",
    language = "English (US)",
    volume = "54",
    pages = "893--902",
    journal = "Journal of Clinical Endocrinology and Metabolism",
    issn = "0021-972X",
    publisher = "The Endocrine Society",
    number = "5",

    }

    TY - JOUR

    T1 - Characterization of the dopaminergic regulation of human prolactin-secreting cells cultured on extracellular matrix

    AU - Bethea, Cynthia

    AU - Ramsdell, J. S.

    AU - Jaffe, R. B.

    AU - Wilson, C. B.

    AU - Weiner, R. I.

    PY - 1982

    Y1 - 1982

    N2 - Human PRL-secreting adenoma cells were cultured on an extracellular matrix (ECM) secreted by bovine corneal endothelial cells, and their sensitivity to dopamine and dopaminergic agonists was examined. Cells plated on ECM attach rapidly, adopt a flattened morphology, and maintain stable PRL secretion for several weeks. Dopamine inhibited PRL secretion from tumor and nontumor cells on ECM in a dose-dependent fashion, with IC 50 values of 243 ± 29 and 76 ± 3.3 nM, respectively, and a maximal inhibition of 80% at 10 -5 M. Apomorphine (APO), dihydroergocryptine (DHE), and bromocriptine (CB-154) also inhibited PRL secretion from adenoma cells in a dose-dependent fashion, with IC 50 values of 24 ± 13, 0.35 ± 0.1, and 0.05 ± 0.01 nM, respectively. Thus, the rank order of potency of the dopamine agonists in inhibiting PRL secretion from adenoma cells was consistent with an interaction at a dopamine receptor: CB-154 > DHE > APO > dopamine. The dopamine antagonists, d-butaclamol, spiperone, domperidone, chlorpromazine, and l-butaclamol, reversed the inhibitory effect of DHE on PRL secretion with IC 50 values of 0.8 nM, 0.9 nM, 1.3 nM, 80 nM, and 30 μM, respectively. The inhibition of PRL secretion was stereoselective, since d-butaclamol was approximately 2000 times more potent than the inactive l-isomer in reversing the effect of DHE. Pieces of adenomas incubated with dopamine before dispersion responded similarly to the dispersed cells plated on ECM, indicating that the ECM did not appear to alter the dopamine-mediated inhibition of PRL. In summary, human PRL-secreting adenoma cells cultured on ECM respond to dopamine in a dose-dependent fashion, but with an IC 50 slightly greater than that observed with normal mammotrophs. The rank order of potency of the dopamine agonists to inhibit PRL secretion (CB-154 > DHE > APO > dopamine) and the rank order of potency of the dopamine antagonists to reverse the inhibitory effect of DHE (d-butaclamol ≃ spiperone ≥ domperidone > chlorpromazine > l-butaclamol) are consistent with an interaction at a dopamine receptor and correlate with the ability of these agents to displace [ 3H]DHE in membrane-binding preparations. These data would argue that human PRL-secreting adenoma cells possess a dopamine receptor, both of high affinity and stereoselective, which mediates the inhibition of PRL secretion.

    AB - Human PRL-secreting adenoma cells were cultured on an extracellular matrix (ECM) secreted by bovine corneal endothelial cells, and their sensitivity to dopamine and dopaminergic agonists was examined. Cells plated on ECM attach rapidly, adopt a flattened morphology, and maintain stable PRL secretion for several weeks. Dopamine inhibited PRL secretion from tumor and nontumor cells on ECM in a dose-dependent fashion, with IC 50 values of 243 ± 29 and 76 ± 3.3 nM, respectively, and a maximal inhibition of 80% at 10 -5 M. Apomorphine (APO), dihydroergocryptine (DHE), and bromocriptine (CB-154) also inhibited PRL secretion from adenoma cells in a dose-dependent fashion, with IC 50 values of 24 ± 13, 0.35 ± 0.1, and 0.05 ± 0.01 nM, respectively. Thus, the rank order of potency of the dopamine agonists in inhibiting PRL secretion from adenoma cells was consistent with an interaction at a dopamine receptor: CB-154 > DHE > APO > dopamine. The dopamine antagonists, d-butaclamol, spiperone, domperidone, chlorpromazine, and l-butaclamol, reversed the inhibitory effect of DHE on PRL secretion with IC 50 values of 0.8 nM, 0.9 nM, 1.3 nM, 80 nM, and 30 μM, respectively. The inhibition of PRL secretion was stereoselective, since d-butaclamol was approximately 2000 times more potent than the inactive l-isomer in reversing the effect of DHE. Pieces of adenomas incubated with dopamine before dispersion responded similarly to the dispersed cells plated on ECM, indicating that the ECM did not appear to alter the dopamine-mediated inhibition of PRL. In summary, human PRL-secreting adenoma cells cultured on ECM respond to dopamine in a dose-dependent fashion, but with an IC 50 slightly greater than that observed with normal mammotrophs. The rank order of potency of the dopamine agonists to inhibit PRL secretion (CB-154 > DHE > APO > dopamine) and the rank order of potency of the dopamine antagonists to reverse the inhibitory effect of DHE (d-butaclamol ≃ spiperone ≥ domperidone > chlorpromazine > l-butaclamol) are consistent with an interaction at a dopamine receptor and correlate with the ability of these agents to displace [ 3H]DHE in membrane-binding preparations. These data would argue that human PRL-secreting adenoma cells possess a dopamine receptor, both of high affinity and stereoselective, which mediates the inhibition of PRL secretion.

    UR - http://www.scopus.com/inward/record.url?scp=0020428629&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0020428629&partnerID=8YFLogxK

    M3 - Article

    VL - 54

    SP - 893

    EP - 902

    JO - Journal of Clinical Endocrinology and Metabolism

    JF - Journal of Clinical Endocrinology and Metabolism

    SN - 0021-972X

    IS - 5

    ER -